Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 09, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure regarding share ownership changes within a specific employee fund and does not contain financial performance data.
Material Changes
The only material change disclosed is a movement in the GlaxoSmithKline US Retirement Savings Plan ("the Plan") on November 04, 2005. The number of Ordinary Share ADRs held by the fund increased from 18,405,230 to 18,453,580 at an average price of $52.43.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the Plan is a discretionary fund for employees and former employees, and that two directors, Dr. J P Garnier and Dr. T Yamada, are potentially interested in the shares held in the fund in the same manner as other employees.
Key Facts for Investor Verification
- The transaction was a passive movement in the US Retirement Savings Plan, not a direct trade by the directors.
- The increase in holdings was 48,350 ADRs.
- The average transaction price was $52.43 per ADR.
- The filing was signed by Simon Bicknell, Company Secretary, on November 09, 2005.